Merck & Co. Jumps Into PD-1/VEGF Bispecific Race With LaNova Deal
The company will in-license LM-299, gaining a PD-1/VEGF bispecific antibody that could help it defend its blockbuster PD-1 franchise against looming competition.
The company will in-license LM-299, gaining a PD-1/VEGF bispecific antibody that could help it defend its blockbuster PD-1 franchise against looming competition.